Search results for " uterine leiomyoma"

showing 3 items of 3 documents

Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.

2022

Objective To evaluate the effect of inhibition of histone deacetylases (HDACs) by suberoylanilide hydroxamic acid (SAHA) treatment of human uterine leiomyoma primary (HULP) cells in vitro on cell proliferation, cell cycle, extracellular matrix (ECM) formation, and transforming growth factor β3 (TGF-β3) signaling. Design Prospective study comparing uterine leiomyoma (UL) vs. adjacent myometrium (MM) tissue and cells with or without SAHA treatment. Setting Hospital and university laboratories. Patient(s) Women with UL without any hormone treatment. Intervention(s) Myomectomy or hysterectomy surgery in women for leiomyoma disease. Main Outcome Measure(s) HDAC activity was assessed by enzyme-li…

AdultAntineoplastic AgentsHistone Deacetylase 1MMP9Histone Deacetylase 6Histone DeacetylasesCyclin D1Transforming Growth Factor beta3Cell proliferation SAHA ULS-ß3 pathway extracellular matrix uterine leiomyomaTumor Cells CulturedHumansViability assayProspective StudiesCell ProliferationVorinostatbiologyLeiomyomaChemistryCell growthCell CycleObstetrics and GynecologyCell cycleMiddle AgedHDAC3Molecular biologyProliferating cell nuclear antigenExtracellular MatrixGene Expression Regulation NeoplasticHistone Deacetylase InhibitorsReproductive MedicineUterine Neoplasmsbiology.proteinFemaleHistone deacetylaseSignal TransductionFertility and sterility
researchProduct

Ulipristal acetate versus leuprolide acetate for uterine fibroids

2012

A b s t r ac t Background The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. Methods In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg). The primary outcome was the proportion of patients with controlled bleeding at week 13, with a prespecified noninferiority margin of −20%. Results Uterine bleed…

Adultmedicine.medical_specialtyUterine fibroidsIntention to Treat AnalysiUrologyAdministration OralEndometriumInjections Intramuscularlaw.inventionchemistry.chemical_compoundYoung AdultEndometriumPrimary outcomeRandomized controlled trialDouble-Blind MethodlawUlipristal acetateSelective progesterone receptor modulatormedicineUterine NeoplasmUlipristalMenorrhagiaGynecologyIntention-to-treat analysisLeiomyomabusiness.industryObstetrics and GynecologyUterine bleedingUterine fibroids uterine leiomyomas uterine bleeding ulipristal acetate leuprolide acetate medical therapyGeneral MedicineNorpregnadieneMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E Ostetriciamedicine.anatomical_structurechemistryAmenorrheaFemalemedicine.symptomLeuprolidebusinessHuman
researchProduct

Characterization of the epigenetic modifications in human uterine leiomyomas and evaluation of their potential as therapeutic targets in vitro

2023

Los miomas o fibromas uterinos (UL) son los tumores benignos más frecuentes en las mujeres en edad reproductiva. A pesar de su elevada prevalencia y de las diferentes opciones de tratamiento, no existe terapia eficaz para la reducción del tamaño de los UL que sea mínimamente invasiva y sin efectos secundarios a largo plazo. Su patología tumoral permanece desconocida, lo que dificulta el desarrollo de tratamientos seguros y eficaces. Por lo tanto, la identificación de los mecanismos moleculares implicados en la generación de UL podría permitir el desarrollo de tratamientos más eficaces. Las modificaciones epigenéticas están implicadas en el desarrollo de los tumores y pueden revertirse media…

epigenetic modificationsUNESCO::CIENCIAS MÉDICAShuman uterine leiomyomas
researchProduct